AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
AbbVie and Pfizer are taking divergent paths to navigate patent expirations and competition. Dig into their financials, risk profiles, and valuation metrics.
Overview
Investors seeking reliable dividends often look to the healthcare sector, but choosing between AbbVie Inc (NYSE:ABBV) and Pfizer Inc (NYSE:PFE) requires a close look at their post-pandemic growth strategies and pipelines.
AbbVie focuses on high-margin specialty medicines in immunology and oncology, while Pfizer operates a broader portfolio spanning vaccines, primary care, and specialized cancer treatments. Both companies are navigating significant patent expirations, making their current research pipelines and acquisition strategies the primary drivers for long-term shareholder value in 2026.
Details
AbbVie focuses on discovering and delivering innovative medicines for complex health issues through a global workforce of roughly 57,000 employees. Its U.S. pharmaceutical sales are heavily concentrated among three major wholesale distributors: McKesson Corporation (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR). Customer concentration like this adds a layer of risk to the business because these three firms account for almost all domestic product sales.
Source
Originally published at www.fool.com.